In June 2026, a two-year Maastricht University trial did something few K2 studies had managed before. It showed MK-7 supplementation measurably slowing coronary artery calcification in people who already had heart disease. The VitaK-CAC trial, published in JAMA Cardiology, gave 180 patients either 360 mcg of MK-7 daily or a placebo for two years. By the end, the treatment group’s calcification had progressed roughly 29% more slowly than placebo, with a 42% reduction in calcium mass score. The researchers called the effect modest and said it needs replication, but it remains one of the more rigorously designed trials to test MK-7 against a hard cardiovascular endpoint rather than a blood marker alone.
Now check a typical bottle of K2 on a pharmacy shelf. A large share is mostly at 45 mcg, 50 mcg, or 90 mcg per serving, a fraction of the dose in that trial, and below the dose behind K2’s best-known bone health data too.
That gap isn’t incidental. In a 12-week Utrecht University trial of 60 adults, researchers compared placebo against 180 mcg and 360 mcg of MK-7 daily and tracked uncarboxylated matrix Gla protein, a marker of how much active vitamin K reaches the tissues that need it. Levels fell 31% in the 180 mcg group and 46% in the 360 mcg group. Roughly doubling the dose nearly doubled the response. K2 doesn’t work on an on-off switch; the effect scales with intake.
The 180 mcg figure isn’t arbitrary. It’s the dose behind the three-year, placebo-controlled trial that much of K2’s bone and heart health messaging traces back to: 244 healthy postmenopausal women given 180 mcg of MK-7 or placebo daily for three years. The treatment group ended up with significantly better bone mineral density and strength than placebo. A follow-up analysis of the same cohort found their arteries stayed measurably more flexible over time, while the placebo group’s stiffened, as arteries tend to with age.
So where does that leave the supplement aisle?
Survey data from GrassrootsHealth, tracking self-reported intake among people already using a K2 supplement, found a median dose of 160 mcg a day, close to the research benchmark. But roughly a quarter of respondents reported taking under 100 mcg. That isn’t automatically wasted money as the Rotterdam Study linked dietary K2 intakes above about 32 mcg a day to lower cardiovascular mortality risk over a decade. But a maintenance dose drawn from population diet data is a different thing from a dose shown in a trial to move a specific clinical marker. A label borrowing bone or heart health language from 180-360 mcg research while shipping 45 mcg of K2 is making a claim its own formulation was never tested against.
Part of the reason traces back to history. Early K2 formulations often anchored dosing to typical dietary intake rather than the amounts used in outcome trials. Part of it is capsule size and cost. The 2026 JAMA Cardiology trial adds a fresh, hard endpoint tied to a specific microgram amount.
One thing works in K2-7’s favor. Even its higher, clinically meaningful doses stay microgram-scale, unlike the MK-4 form, which needs milligram-range dosing for comparable effect. Hitting a real 180 mcg or 360 mcg label claim with MK-7 doesn’t require a bigger capsule or budget.
How TerraQuino Helps
TerraQuino supplies Vitamin K2-7 (MK-7) to nutraceutical brands building toward exactly that gap, between what’s printed on a label and what the research supports. The ingredient is produced through a controlled fermentation process built for batch-to-batch consistency, manufactured in cGMP-compliant facilities, and formulated for tablets, capsules, softgels, sachets, and liquids, so a brand can move toward an evidence-based dose without redesigning its format. For a formulator weighing a 45mcg SKU against one that can stand behind a real health claim, that ingredient-level consistency is where the decision starts.
The VitaK-CAC researchers’ own caution is worth borrowing for any K2 claim i.e. match dose, population, and outcome to what was actually studied, rather than assuming any amount of K2 does the same job.
Frequently Asked Questions
What dose of vitamin K2 (MK-7) actually has clinical research behind it?
The most reliable data is that of 180 mcg/day, which was used for the three years in the Knapen et al. study on bone density and arterial elasticity, and that of 360 mcg/day, which will be used for the VitaK-CAC study on coronary artery calcification published in JAMA Cardiology in 2026.
Does that mean 45 mcg or 50 mcg K2 supplements are a waste of money?
That is not always the case, as the Rotterdam Study found that high dietary K2 intakes of around 32 mcg per day reduced the risk of dying from cardiovascular disease after ten years. This is a smaller dosage, but it is enough to meet normal requirements.
Is there a safe upper limit for vitamin K2?
There is no safe upper limit intake value set as well. However, studies involving the administration of up to 360 micrograms per day for two years have not shown any major side effects, apart from some instances of minor digestive issues. The issue to be aware of in terms of potential side effects is medication interaction.
How can a formulator confirm an MK-7 ingredient will deliver its labeled dose through shelf life?
Insist on batch-to-batch stability and fermentation information and not merely the Certificate of Analysis during manufacturing process. Potency may vary with uncontrolled sources; one of the reasons why the end-product may come out with lower potency than indicated on the label after some months.
